Connect Biopharma Files June 2024 6-K Report

Ticker: CNTB · Form: 6-K · Filed: Jun 12, 2024 · CIK: 1835268

Sentiment: neutral

Topics: regulatory-filing, foreign-private-issuer

TL;DR

Connect Biopharma dropped a June 6-K, standard foreign issuer update.

AI Summary

Connect Biopharma Holdings Limited filed a Form 6-K on June 12, 2024, reporting its activities for the month of June 2024. The company, incorporated in E9 with a fiscal year end of December 31, is based in San Diego, CA, and operates in the Pharmaceutical Preparations industry. This filing is a routine report for foreign private issuers.

Why It Matters

This filing provides an update on Connect Biopharma's ongoing activities as a foreign private issuer, which is important for investors tracking the company's regulatory compliance and operational status.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial or operational news that would typically increase risk.

Key Players & Entities

FAQ

What type of filing is Connect Biopharma Holdings Limited submitting?

Connect Biopharma Holdings Limited is submitting a Form 6-K, which is a Report of Foreign Private Issuer.

What is the Commission File Number for Connect Biopharma Holdings Limited?

The Commission File Number for Connect Biopharma Holdings Limited is 001-40212.

What is the Standard Industrial Classification code for Connect Biopharma Holdings Limited?

The Standard Industrial Classification code for Connect Biopharma Holdings Limited is 2834, which corresponds to Pharmaceutical Preparations.

Where is Connect Biopharma Holdings Limited's principal executive office located?

Connect Biopharma Holdings Limited's principal executive office is located at 12265 El Camino Real, Suite 350, San Diego, CA 92130, USA.

What period does this Form 6-K report cover?

This Form 6-K reports on activities for the month of June 2024.

Filing Stats: 2,702 words · 11 min read · ~9 pages · Grade level 12.4 · Accepted 2024-06-12 16:47:23

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated June 12, 2024 CONNECT BIOPHARMA HOLDINGS LIMITED By s Steven Chan Name Steven Chan Title Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing